Loading...
•
Dec 31, 2025
Verastem Q4 2025 Earnings Report
Verastem Q4 2025 Earnings Report
Key Takeaways
Verastem Oncology reported a transformative fourth quarter driven by the commercial launch of AVMAPKI FAKZYNJA CO-PACK, which generated $17.5 million in net product revenue. While operating expenses increased significantly due to commercialization and R&D activities, the company strengthened its balance sheet through a public offering and warrant exercises, extending its cash runway into the first half of 2027.
AVMAPKI FAKZYNJA CO-PACK generated $17.5 million in net product revenue for Q4 2025 following its May 2025 FDA approval.
The company reported a GAAP net loss of $32.9 million for the quarter, an improvement from the $64.6 million loss in the prior year period.
Cash, cash equivalents, and investments totaled $205 million at year-end, with pro-forma cash of $234.4 million including January warrant exercises.
Clinical development of VS-7375 is accelerating with plans for Phase 2 registration-directed trials in pancreatic, lung, and colorectal cancers.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Verastem is focused on maximizing adoption of its approved LGSOC treatment while advancing its KRAS G12D inhibitor pipeline through key clinical milestones in 2026 and 2027.
Positive Outlook
- Expected cash runway into first half of 2027
- Topline readout of primary endpoint in RAMP 301 trial expected in mid-2027
- Report early data from VS-7375-101 trial in 1H 2026
- Initiate CRC combination expansion cohort for VS-7375 in 1H 2026
- Complete enrollment in VS-7375 monotherapy expansion cohorts in 2H 2026
Challenges Ahead
- NCCN Guidelines did not expand recommendation to include KRAS wild-type recurrent LGSOC
- Operating expenses expected to remain high due to commercialization and R&D
- Continued approval for LGSOC may be contingent upon confirmatory trial results
- Maximum tolerated dose for VS-7375 not yet reached, requiring further escalation
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...